rAAV Gene Therapy for CLN2 Disease Motor Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CLN2 disease, such as enzyme replacement therapy, require frequent administrations and do not provide durable and long-term TPP1 enzymatic activity in the central nervous system, posing a significant unmet need for alternative therapies that can effectively stabilize motor and language functions without high patient burden.
Innovation Solution
Administration of a recombinant adeno-associated virus (rAAV) into the central nervous system, comprising an AAV capsid with a vector genome containing an AAV 5′ inverted terminal repeat sequence, a promoter, a CLN2 coding sequence encoding human TPP1, and an AAV 3′ ITR, which results in improved TPP1 activity and clinical benefits like reduced seizures and improved quality of life measures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is administered to treat CLN2 disease, then TPP1 enzymatic activity is restored in the central nervous system, but frequent repeated administrations are required due to short half-life, creating high patient burden and treatment complexity
Solution Approach 1:
The patent uses AAV vectors to deliver functional CLN2 gene copies that enable patient cells to self-produce TPP1 enzyme continuously. The transduced cells serve themselves by expressing the therapeutic enzyme indefinitely, eliminating the need for repeated external administrations and the complex infrastructure required for frequent infusions
Solution Approach 2:
The patent performs preliminary genetic modification by administering AAV vectors that integrate functional CLN2 genes into patient cells before disease progression becomes irreversible. This preliminary genetic correction establishes durable TPP1 production capacity that persists throughout the patient's life, preventing rather than merely treating the enzyme deficiency
2Reliability
If enzyme replacement therapy is used to stabilize motor function, then clinical symptoms are managed, but the therapy requires biweekly infusions every two weeks, resulting in significant patient burden and reduced quality of life
Solution Approach 1:
By transferring the CLN2 gene via AAV to patient cells, the body's own cells are programmed to continuously produce TPP1 enzyme. This self-sustaining approach eliminates the need for repeated hospital visits and complex infusion procedures, dramatically reducing patient burden while maintaining reliable motor function stabilization
Solution Approach 2:
The patent transitions from periodic external enzyme administration (biweekly infusions) to continuous endogenous enzyme production. The AAV-mediated gene transfer creates a permanent, non-periodic source of TPP1 that is continuously available to stabilize motor function without requiring repeated treatment intervals
3Reliability
If AAV2 vector is used to deliver TPP1, then enzyme secretion into cerebrospinal fluid is achieved, but the vector does not penetrate brain parenchyma and does not target neurons, limiting therapeutic benefit
Solution Approach 1:
The patent applies local quality by selecting different AAV serotypes (AAV9, AAVrh10, AAV2.5) with specific tropism characteristics matched to target tissues. AAV9 and AAVrh10 are selected for their demonstrated ability to penetrate brain parenchyma and transduce neurons, providing locally optimized gene delivery to the specific compartments where TPP1 is most needed
Solution Approach 2:
The patent changes the key parameter of viral capsid composition by using different AAV serotypes with varying tissue penetration and transduction properties. This parameter change enables the vector to adapt to different anatomical barriers and cell types, achieving both CSF penetration and brain parenchyma transduction that AAV2 cannot accomplish alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves significant clinical improvements, including stabilization of motor and language functions, reduction in seizure frequency and duration, and improved quality of life, with potential for long-term TPP1 activity and reduced need for frequent treatments.
Implementation Method 1
Administration of a recombinant adeno-associated virus (rAAV) into the central nervous system, comprising an AAV capsid with a vector genome containing an AAV 5′ inverted terminal repeat sequence, a promoter, a CLN2 coding sequence encoding human TPP1
Data Source
AI summary
Provided herein are methods and compositions for treatment of CLN2 Disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5′ inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3′ ITR. Also provided herein are methods of treating CLN2 Disease comprising administering to a subject in need thereof the rAAV described herein via more than one route. Also provide herein are pharmaceutical compositions comprising the rAAV described herein and related methods of treating CLN2 Disease.